


SUPPLEMENTARY MATERIAL



Supplementary Figure 1. Topical ozone therapy does not change the

differentiated proportion of Th1, Th2 and Treg subsets

Proportions of Th1 (a), Th2 (b), and T_{reg} (c) cells from mouse spleens and lymph nodes were assessed by flow cytometry in four groups, e.g. Ctrl, IMQ, IMQ+Vehicle, and IMQ+Ozone.

Note: * = $P < 0.05$; ** = $P < 0.01$; *** = $P < 0.001$; NS = no statistical significance.

Supplementary Table 1. Clinical information of enrollees

No.	Age (years)	Gender	PASI score		
			Before treatment	1 week after treatment	2 weeks after treatment
1	35	Male	8.2	6.1	5.0
2	42	Male	26.5	14.9	12.6
3	26	Male	8	5.6	6.6
4	51	Male	25	16.5	12.4
5	24	Male	12.4	10.2	8.0
6	40	Male	12	7.5	5.0
7	34	Female	22.5	17.2	10.5
8	49	Male	19	16.5	16.0
9	28	Female	18	12.4	9.8
10	22	Female	24	15.6	10.9

Supplementary Table 2. Primer sequences for quantitative PCR.

H-IL17A-F:5'-ATTACTACAACCGATCCACCTC-3'	H-IL17A-R:5'-TGGTAGTCCACGTTCCCAT-3'
H-IL17F-F:5'-AGTAAGCCACCAGCGCAACATG-3'	H-IL17F-R:5'-CTCAGAAAGGCAAGCCCAATA-3'
H-IL6-F:5'-AATTCGGTACATCCTCGACGGC-3'	H-IL6-R:5'-GCCAGTGCCTCTTTGCTGCITT-3'
H-TNF α -F:5'-GGACACCATGAGCACTGAAAGC-3'	H-TNF α -R:5'-TGCCACGATCAGGAAGGAGAAG-3'
H-TGF β -F: 5'-GCAACAATTCCTGGCGATAC-3'	H-TGF β -R: 5'-AAGGCGAAAGCCCTCAAT-3'
H-IFN γ -F:5'-CATCCAAAAGAGTGTGGAGACA-3'	H-IFN γ -R: 5'-TGCTTTGCGTTGGACATTCAAG-3'
H-IL10-F:5'-AAGACCCAGACATCAAGGCG-3'	H-IL10-R:5'-AGGCATTCTTCACCTGCTCC-3'
H-P65-F:5'-AGGGAAATGCCTCTGTGAGCT-3'	H-P65-R:5'-GCAAGAAAGAAGAGGGGTTTGA-3'
H-P50-F:5'-GAGGGAGGCGATCTGATACA-3'	H-P50-R:5'-CTGGACATCAACCTTCAAGC-3'
H-RORC-F:5'-AGGCCATTCAGTACGTGGTGA-3'	H-RORC-R:5'-CGTGCGTTGTCAGCATTGTAG-3'
H-GAPDH-F:5'-ATGGGAAGGTGAAGGTCG-3'	H-GAPDH-R:5'-GGGTCATTGATGGCAACAATA-3'
M-III17a-F:5'-ATGCTGTTGCTGCTGCTGAG-3'	M-III17a-R:5'-GGAAGTCCTTGGCCTCAGTG-3'
M-III17f-F:5'-GGAGGTAGCAGCTCGGAAGA-3'	M-III17f-R:5'-GGAGCGTTCTGGAATTCAC-3'
M-IL10-F:5'-CTTACTGACTGGCATGAGGA-3'	M-IL10-R:5'-GCATTAAGGAGTCGGTTAGC-3'
M-IFN γ -F: 5'-AGACAATCAGGCCATCAGCA-3'	M-IFN γ -R: 5'-CAACAGCTGGTGGACCACTC-3'
M-RORc-F:5'-GGACAGGAGCCAAGTTCTCA-3'	M-RORc-R:5'-CACAGGTGATAACCCCGTAGTGG-3'
M-STAT3-F:5'-GTTGGAGCAGCATCTTCAGG-3'	M-STAT3-R:5'-GCATGTCTCCTTGGCTCTTG-3'
M-P50-F: 5'-ATGGTGGTTGGCTTTGCAAA-3'	M-P50-R:5'-TGCACCAGAAGTCCAGGATT-3'
M-P65-F: 5'-TCATCGAACAGCCGAACCAA-3'	M-P65-R: 5'-CAGCCCATAGGGAACCTACC-3'
M-CXCL1-F: 5'-GACTCCAGCCACACTCCAAC-3'	M-CXCL1-R: 5'-TGACAGCGCAGCTCATTG-3'
M-CXCL2-F:5'-AAAATCATCCAAAAGATACTGAACAA-3'	M-CXCL2-R:5'-CTTGGTTCTTCCGTTGAGG-3'

M-GAPDH-F: 5'-ATGGTGAAGGTCGGTGTGA-3'	M-GAPDH-R: 5'-AATCTCCACTTTGCCACTGC-3'
M-IL-17c-F: 5'-CCTCTAGCTGGAACACAGTGC-3'	M-IL-17c -R:5'-GCGGTTTCATCTGTGTCG-3'
M-IL-22-F: 5'-TGACGACCAGAACATCCAGA-3'	M-IL-22-R:5'-AATCGCCTTGATCTCTCCAC-3'
M-IL-6-F: 5'-GCTACCAAACCTGGATATAATCAGGA-3'	M-IL-6-R:5'-CCAGGTAGCTATGGTACTCCAGAA-3'
M-S100A8-F: 5'-TCCTTGCGATGGTGATAAAA-3'	M-S100A8-R: 5'-GGCCAGAAGCTCTGCTACTC-3'
M-S100A9-F: 5'-GACACCCTGACACCCTGAG-3'	M-S100A9-R: 5'-TGAGGGCTTCATTCTCTTCTC-3'
M-TNF- α -F: 5'-CTGTAGCCCACGTCGTAGC-3'	M-TNF- α -R: 5'-TTGAGATCCATGCCGTTG-3'
M-VEGF-F: 5'-AAAAACGAAAGCGCAAGAAA-3'	M-VEGF-R: 5'-TTTCTCCGCTCTGAACAAGG-3'
M-CXCL3-F: CCCCAGGCTTCAGATAATCA	M-CXCL3-R: TCTGATTAGAATGCAGGTCCTT
M-IL-1 β -F: GAAATGCCACCTTTTGACAGTG	M-IL-1 β -R: TGGATGCTCTCATCAGGACAG
M-IL-8-F: TGCTCAAGGCTGGTCCAT	M-IL-8-R: GACATCGTAGCTCTTGAGTGCA
M-defensinB14-F: TGAGGCTTCATTATCTGCTATTTG	M-defensinB14-R: TTTCGGAGGGTTTTTGGTAG
M-S100A7-F: GCCTCGCTTCATGGACAC	M-S100A7-R: CGGAACAGCTCTGTGATGTAGT
M-K10-F: GAACAACCTGCAGAAAAGAATCG	M-K10-R: TGTGGTGAGTTCCTTGCTCTT
M-Filaggrin-F: GGACTCTGAGAGGCGATCTG	M-Filaggrin-R: TGCTCCCGAGAAGATCCAT
M-Loricrin-F: GGTGCAACGGAGACAACA	M-Loricrin-R: CATGAGAAAGTTAAGCCCATCG

Note: H = human; M = mouse; F = forward primer; and R = reverse primer.